A battle for people! Those flowing CMO (Chief Medical Officer).

，、CMO。

CMO。，——

，。，，CMO，，CMO，。

，。，，CMO。

、。，，CMO，。

、。，，，CMO，CMO。

CMO？

，，，。，，CMO。

，、，200。CMO500，CMO300,“200”，。

，David－Lu，CMO，，CMO，。

，CMOCMO，，，10%—20%。

CMO（）：

202131，，，。

，Hengrui TherapeuticsCMO，CEO。，。

2021218，，（CMO）。

20。，，。，、GSK、-。

20212，、CMO，。

，。

On January 6, 2021, Yuheng Biological announced that Dr.

Hei Yongjiang has more than 20 years of related work experience in the oncology field of internationally renowned pharmaceutical companies.

Klingyuan Michael Silverman

In January 2021, Coolingyuan appointed Michael Silverman, a member of the American College of Physicians, as the CMO.

Li Xiaoyan Visor Biology

In January 2021, Vision Biotech appointed Li Xiaoyan as the CMO.

Prior to this, Xiaoyan Li served as the Executive Director of Clinical Development at Allergan/Abbvie and also at Pfizer.

Melissa Palmer, MD, Kam Lai, a subsidiary of Kolly Pharmaceuticals

On November 30, 2020, Gan Lai, a wholly-owned subsidiary of Golly Pharmaceuticals, announced that Melissa Palmer, an internationally renowned expert in the field of liver diseases and a doctor of medicine, joined the company on December 1 as the chief medical officer.

Prior to joining Gan Lai, Dr.

Lepu Biotech Frederick H.

Dr.

Prikin Yao Yi

In November 2020, Yao Yi became the CMO of Prikin.

Yao Yi has joined the FDA Biologics and Biological Products Evaluation Center in 2002.

Ruibo Biotech Wang Hanming

In November 2020, Wang Hanming joined Guangzhou Ruibo Biotech as a VP responsible for the registration and clinical research of new crown, influenza mRNA vaccines and RNAi drugs.

Wang Hanming (formerly) CMO of Than Shwe Biosciences has worked in Sanofi Pasteur, Pfizer R&D, CRO, Biotech Cellular Immunotherapy.

Connaught Micromedicine Wish Huan

In September 2020, Zhu Huan joined Innomicro Medicine.

Zhu Huan has led a number of clinical studies on tumor and immunotherapy in major companies such as Novartis, Pfizer, Amgen, Johnson & Johnson, Halozyme Theraoeutics.

Fortune Huaning Dr.
Bao Jing

In August 2020, Hongyun Huaning, an innovative pharmaceutical company, announced that medical scientist Dr.
Jing Bao joined Hongyun Huaning as the Chief Medical Officer (CMO), leading and responsible for the clinical development of new drugs, medical strategies and team building.

Bao Jing has more than 30 years of experience in clinicians, cancer molecular immunology research, drug development and global multi-center clinical trials.
Dr.
Bao also worked for the National Institutes of Health (NIH) for 14 years, leading and managing more than 20 global multi-center clinical trials of drugs.
Before joining Hongyun Huaning, Bao Jing worked as the CMO of Livzon Pharmaceutical Group.

PatriciaKeegan

On August 10, 2020, Junshi Bio announced the appointment of Dr.
Patricia Keegan as Chief Medical Officer (CMO), responsible for the leadership and management of the company's clinical development projects, and accelerate the company's products to enter the commercialization stage on a global scale.

Dr.
Keegan has more than 30 years of experience in tumor treatment, clinical research and drug regulatory supervision.
Prior to joining Junshi Bio, Dr.
Keegan worked for the U.
S.
Food and Drug Administration (FDA) for 30 years.
She served as the Medical Review Officer of the Oncology Products Department, the Deputy Director of the Clinical Trial Design and Analysis Department, and the Director of the Oncology Products Department.
The last post was Deputy Director of the Oncology Center for Excellence (OCE).

Heqirui Medicine Wang Xiangling

In July 2020, Wang Xiangling joined Herqirui Medicine and officially became the CMO.

From 2006 to 2020, Dr.
Wang served as Vice President of Medicine of Weisheng Pharmaceutical, Director of Clinical Research of Sanofi China R&D Center, Head of Metabolic Therapy of Novartis China, Senior Medical Manager of Novo Nordisk China; responsible for the formation of clinical medical team And management, the formulation of clinical research strategies, the formulation of clinical plans, and trial operations.

Before entering the industry, Dr.
Wang worked in the Second Affiliated Hospital of Tsinghua University (Yuquan Hospital) for 12 years.
He is the deputy chief physician of the Department of Endocrinology and has extensive clinical experience in the field of endocrine diseases.

Huayi Technology Chang Yumin

In July 2020, Huayi Technology announced that the CMO will be appointed by Zhang Yumin, Ph.
D.
in nuclear medicine and radiopharmaceuticals, and concurrently as the company's vice president.

Zhang Yumin was the Chief Technology Officer of Beijing Xiantong International Pharmaceutical Technology Co.
, Ltd.
(May 2018-July 2020).
Prior to this, he served as the Chief Scientist of Sub-Imaging in the Translational Science Division at Abbott/AbbVie (December 2006-May 2018).

Force Life Sciences Luo Feng

In July 2020, Luo Feng joined Force Life Sciences as the senior vice president and CMO.

In the process of drug development for more than 20 years, Luo Feng has led and supported NDA projects for several new oncology drugs, the most famous of which are the EGFR inhibitors Abivertinib, Erdafitinib and Dasatinib for the treatment of lung cancer.

Genxi Bio-Martina Sersch

In July 2020, Martina Sersch joined Genxi Biotech as CMO.

He used to serve as CMO in a CAR-T cell and gene therapy company listed on Nasdaq.

Leading Medical Matthias Straub

On June 15, 2020, Lingsheng Medical officially appointed Matthias Straub as the CMO.

Dr.
Matthias Straub has worked in multinational companies such as Ciba Geigy, Solvay Pharmaceuticals and Abbott.

Jinsai Pharmaceutical CMO (non-oncology field) Luo Tianhong

In April 2020, he served as CMO in the non-oncology field of Jinsai Pharmaceutical.

Luo Tianhong used to be the medical director of Eli Lilly Asia’s endocrinology field and the head of Sanofi’s China Medical Affairs Department.
Before joining Kinsey Pharmaceuticals, Mr.
Luo Tianhong served as the head of the medical department in Mainland China and Hong Kong at Bristol-Myers Squibb.
During his career, he has participated in the research and development of important products in many fields and post-marketing clinical research, such as the related research of Bibiida, Futaiao, Laidse, Odivo and other products.

Weisheng Pharmaceutical Industry Yang Jun

In April 2020, Weisheng Pharmaceutical appointed Yang Jun as the company's CMO, mainly responsible for the company's product development, registration and medical affairs.
Prior to this, she served as Senior Medical Director of Eli Lilly China in the field of diabetes.

Alis Medicine Mou Yanping

On March 26, 2020, Ms.
Mou Yanping, former managing director of Merck’s Oncology Division, joined Alis Medical as the CEO.

Ms.
Mou Yanping has served many well-known multinational pharmaceutical companies including GlaxoSmithKline, AstraZeneca, Johnson & Johnson, and Merck, and has accumulated extensive experience in leading sales, marketing and comprehensive management.

Erics Medical Li Ling (resigned)

On March 26, 2020, Ms.
Li Ling, former vice president of clinical development of Hengrui Pharmaceuticals, joined Alis Pharmaceuticals as the chief medical officer.
(It is rumored to have resigned)

Ms.
Li Ling has more than 20 years of experience in new drug clinical development and personnel management, involving different therapeutic fields, including immunology, oncology, hematology, cardiovascular disease, diabetes, neuroscience, etc.
He has served as TA Head, Clinical Operations Leader, Global R&D Lead, and Clinical Development Assistant in many multinational pharmaceutical companies and CRO companies such as Xi’an Janssen, Quintiles, Bayer, Simcere Pharmaceuticals, Hengrui Pharmaceuticals, and local large pharmaceutical companies President and other positions.

Reindeer Medical Wang Wen

From March 2020, Wang Wen has served as the CMO of Reindeer Medical.

Wang Wen has been systematically engaged in cell therapy for more than ten years since 2006.
He has worked in Sibiman Biology, WuXi Junuo, Simcere Pharmaceuticals.
As the main member of the project, Wang Wen successfully applied for China's first CAR-T registration clinical trial targeting CD19.

Hutchison Whampoa Medicine He Li Jing

In February 2020, Hutchison Whampoa Pharmaceuticals has announced the appointment of He Li Jing as the senior vice president and chief medical officer of Hutchison Whampoa Pharmaceuticals and the head of clinical and registration in China.

Before joining Hutchison Whampoa, He Lijing was the vice president of GSK and the head of China's prescription drug research and development and medical affairs department.

Kewang Pharmaceutical Qinxueke

In January 2020, Kewang Pharmaceutical appointed Steve Chin as CMO.

Prior to this, Qin Xuke served as senior medical director at AstraZeneca.
Earlier, he also served as the leader of Eli Lilly's global gastrointestinal oncology discipline.

Impair Pharmaceuticals Xie Zhiyi

In January 2020, Impair Pharmaceuticals officially announced the appointment of Dr.
Zhiyi Xie as senior vice president and chief medical officer, responsible for the global clinical strategy and development of the company's product pipeline.

Zhiyi Xie has more than ten years of clinical experience in oncology, hematology, and global clinical trial management experience.
Dr.
Xie used to serve as the Chief Medical Officer of Asikang Pharmaceutical Company.
As a medical leader, he led the development and completion of multiple single-country and international multi-center clinical trials, ranging from Phase I trials to key global studies.

Saisheng Pharmaceutical Guo Xiaoning

Guo Xiaoning joined Saisheng in 2020 and is now responsible for the company's R&D management.

Before joining the company, Dr.
Guo served as a senior scientist at AstraZeneca Pharmaceutical Co.
, Ltd.
from 2007 to 2011; from 2012 to 2014 as the project leader of Johnson (Shanghai) Medical Devices Co.
, Ltd.
; from 2014 to 2018, as Covance , Inc.
, senior director and head of clinical drug development; from 2018 to 2020, he has served as deputy general manager and clinical development and regulatory affairs director of Jiaochen Biomedical Technology (Shanghai) Co.
, Ltd.

Reference materials:

With freehand brushwork: "Bao Jing became the chief medical officer of Hongyun Huaning, and Qirui and other institutions appoint CMO"

The same freehand: "Directory of Chief Medical Officer (CMO) of China New Drug Company"